比利时重症新生儿和儿童万古霉素床旁模型引导精准给药(BENEFICIAL试验):多中心随机对照试验
BENEFICIAL试验在比利时7家医院14个儿科/新生儿重症及血液肿瘤病房随机分配332例18岁以下重症患者,比较模型引导精准给药(MIPD)与标准治疗药物监测(TDM)对万古霉素药效学达标及安全性的影响。
要点
- 两组严重不良事件发生率均为5%,MIPD组1例死亡可能与给药方式相关。
核心结论
- 基于AUC的MIPD可提高万古霉素AUC/MIC目标达成率且危害风险低。
- 鉴于高万古霉素AUC是急性肾损伤的明确驱动因素,本试验中观察到的较低累积暴露支持在重症儿童中使用MIPD,尤其是需要长疗程或存在额外急性肾损伤风险因素者。
研究设计与样本
- BENEFICIAL试验为实用性、个体随机、对照优效性试验,在比利时7家医院14个儿科或新生儿重症监护及血液肿瘤病房进行。
- 纳入标准为18岁以下、因疑似或确诊革兰阳性菌感染开始静脉万古霉素治疗的危重患者;关键排除标准包括体外支持、严重急性肾损伤、慢性肾病和濒临死亡。
- 干预组使用MIPD给药计算器确定起始和后续剂量,并在治疗最初数小时增加TDM采样;对照组接受标准治疗TDM。
- 患者按1:1随机分配至MIPD或标准TDM组,采用按病房类型分层的置换区组随机化,通过安全网络界面分配;患者、家属和生物统计师设盲,治疗医师和药师不设盲。
- 主要结局为治疗开始后24-48小时假设MIC为1 mg/L时24小时AUC/MIC比值在400-600 mg·h/L的患者比例;关键次要结局为新发或加重急性肾损伤或死亡的比例;在意向性治疗(ITT)人群中评估,安全性在所有至少接受一剂万古霉素的患者中评估。
主要发现
- 2020年12月28日至2023年12月14日共随机分配332例年龄1天至18岁患者,标准组165例,干预组167例;18例因延迟同意未获知情同意被排除,最终分析314例(男179例,女135例)。
- 严重不良事件:标准组158例中8例(5%),干预组156例中8例(5%);干预组1例患者死于至少可能与万古霉素给药方式相关的严重不良事件。
关键数值与推荐
- 主要结局达标定义为24小时AUC/MIC比值在400-600 mg·h/L(假设MIC为1 mg/L),于治疗开始后24-48小时评估。
- 严重不良事件发生率两组均为5%(标准组8/158,干预组8/156)。
临床怎么用
- 对重症新生儿和儿童使用万古霉素时,可采用基于贝叶斯软件的MIPD结合早期采样估算AUC,以提高AUC/MIC目标达成率。
- MIPD尤其可能适用于需要长疗程万古霉素或存在额外急性肾损伤风险因素的危重患儿。
- 应用MIPD时仍需监测急性肾损伤和不良事件,尽管本试验中MIPD组累积暴露较低。
局限性
- 急性肾损伤或死亡结局在两组间无统计学显著差异,置信区间较宽。
- 治疗医师和药师未设盲,可能存在实施偏倚。
- 18例随机分配患者因延迟同意未获知情同意被排除分析。
- 研究在比利时7家医院进行,外推至其他医疗环境需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vancomycin is widely used to treat serious Gram-positive infections but is difficult to dose given its narrow therapeutic index and risk of acute kidney injury at high doses. We aimed to study whether model-informed precision dosing (MIPD) of vancomycin, compared with standard-of-care therapeutic drug monitoring (TDM), increases pharmacokinetic and pharmacodynamic target attainment, is safe, and reduces vancomycin-associated acute kidney injury in children with severe illness. METHODS: The BENEFICIAL trial is a pragmatic, individually randomised, controlled superiority trial done in 14 paediatric or neonatal intensive care and haemato-oncology units in seven hospitals in Belgium. Critically ill patients younger than 18 years initiating intravenous vancomycin for suspected or confirmed Gram-positive infection were eligible. Key exclusion criteria were extracorporeal support, severe acute kidney injury, chronic kidney disease, and imminent death. The intervention combined the use of an MIPD dosing calculator for starting and follow-up doses, with extra sampling for TDM in the first hours of treatment compared with standard-of-care TDM. Patients were randomly assigned (1:1) to MIPD or standard-of-care TDM of vancomycin using stratified permuted blocks by ward type. Allocation occurred via a secure web interface; patients, families, and the biostatistician were masked, but treating physicians and pharmacist staff were not. The intervention used Bayesian software with early sampling to estimate AUC. The primary outcome was the proportion of patients with a 24-h AUC-to-MIC ratio of 400-600 mg·h/L, assuming a minimum inhibitory concentration of 1 mg/L, 24-48 h after treatment initiation. A key secondary outcome was the proportion of patients with new or worsening acute kidney injury or death. These outcomes were assessed in the intention-to-treat (ITT) population (all randomly assigned patients who provided informed consent). Safety was evaluated in all patients who received at least one dose of vancomycin. This trial is registered with ClinicalTrials.gov (NCT04666948) and the EU Clinical Trials register (EudraCT 2019-004538-40), and is closed to recruitment. FINDINGS: Between Dec 28, 2020, and Dec 14, 2023, 332 patients aged between 1 day and 18 years were randomly assigned, 165 to the standard-of-care group and 167 to the intervention group. 18 participants were excluded from the analysis when their deferred consent was not followed by informed consent; therefore 314 patients (179 male and 135 female) were included in the analysis. Target AUC-to-MIC ratio attainment at 24-48 h was found in 82 (53·9%) of 152 patients with available data in the standard-of-care group and 112 (71·8%) of 156 in the MIPD group (absolute difference 18·9% [1·7 to 34·7]). The proportion of patients with acute kidney injury or all-cause mortality was numerically but not significantly lower in the intervention group (26 [16·9%] of 154 vs 19 [12·4%] of 153; absolute difference -4·5% [95% CI -11·6 to 3·5]). Serious adverse events occurred in eight (5%) of 158 patients in the standard-of-care group and eight (5%) of 156 patients in the intervention group. One patient in the intervention group died due to a serious adverse event at least possibly related to the vancomycin administration method. INTERPRETATION: AUC-based MIPD improves AUC-to-MIC ratio-based target attainment and has a low risk of harm. Given that elevated vancomycin AUC is a well established driver of acute kidney injury, the lower cumulative exposure observed in this trial support the use of MIPD in severely ill children, particularly in those who require long treatment durations or present with additional acute kidney injury risk factors. FUNDING: Belgian Federal Knowledge Centre Trials Programme.
引用
- De Cock PA, Colman R, Smits A, et al. Bedside model-informed precision dosing of vancomycin in severely ill neonates and children in Belgium (the BENEFICIAL trial): a multicentre, randomised controlled trial. Lancet Child Adolesc Health. 2026. PMID: 41974145. doi:10.1016/S2352-4642(25)00385-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。